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English setting
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Abstract
Background: Multiple criteria decision analysis (MCDA) has appeared as a methodology to address limitations of
economic evaluation in health technology assessment (HTA), however there are limited empirical evidence from real
world applications. The aim of this study is to test in practice a recently developed MCDA methodological framework
known as Advance Value Framework (AVF) through a proof-of-concept case study engaging multiple stakeholders.
Methods: A multi-attribute value theory methodological process was adopted involving problem structuring, model
building, model assessment and model appraisal phases. A facilitated decision analysis modelling approach was used
as part of a decision conference with thirteen participants. An expanded scope of the National Institute for Health and
Care Excellence (NICE) remit acted as the study setting with the use of supplementary value concerns. Second-line
biological treatments were evaluated for metastatic colorectal cancer (mCRC) patients having received prior chemotherapy,
including cetuximab monotherapy, panitumumab monotherapy and aflibercept in combination with FOLFIRI
chemotherapy. Initially 18 criteria attributes were considered spanning four value domains relating to therapeutic impact,
safety profile, innovation level and socioeconomic impact.
Results: Nine criteria attributes were finally included. Cetuximab scored the highest overall weighted preference value
score of 45.7 out of 100, followed by panitumumab with 42.3, and aflibercept plus FOLFIRI with 14.4. The relative weights
of the two most important criteria (overall survival and Grade 4 adverse events) added up to more than the relative weight
of all other criteria together (52.1%). Main methodological limitation was the lack of comparative clinical effects across
treatments and challenges included the selection of “lower” and “higher” reference levels on criteria attributes, eliciting
preferences across attributes where participants had less experience, and ensuring that all attributes possess the right
decision theory properties.
Conclusions: This first application of AVF produced transparent rankings for three mCRC treatments based on their value,
by assessing an explicit set of evaluation criteria while allowing for the elicitation and construction of participants’ value
preferences and their trade-offs. It proved it can aid the evaluation process and value communication of the alternative
treatments for the group participants. Further research is needed to optimise its use as part of policy-making.
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Background
The assessment and appraisal of new and expensive medi-
cines by health technology assessment (HTA) bodies,
health insurers, and gatekeeper agencies has received con-
siderable attention in recent years, especially in countries
with publicly funded health care systems. This is a conse-
quence of negative, and sometimes controversial, recom-
mendations on the funding of new medicines due to their
high costs. In several cases these medicines relate to treat-
ments for severe diseases with high burden, leading to
high patient dissatisfaction and public criticism.
As a result, the methodological aspects for assessing
and appraising new medicines have been placed under
scrutiny. The use of QALYs (quality adjusted life years)
as part of economic evaluations in HTA, although it is a
reasonable measure of health gain, it has been argued as
inadequate to express the wider patient and societal per-
spective. This is partially because it does not reflect
other dimensions of social value relating to the burden
of the disease, the innovation level of interventions and
their wider socioeconomic impact [1, 2], therefore acting
as an incomplete value metric for cancer treatments and
genetic testing [3, 4]. These limitations have led often to
the ad hoc and non-systematic use of additional parame-
ters of value by policy-makers which, due to lack of
transparency, have given an impression of inconsistency
in evidence appraisal and decision-making. Decision
controversies however primarily exist because of varying
value perspectives, with disagreement being evident
among different stakeholders [5]. Therefore, for any de-
cision outcome to be ultimately understood and
regarded as “rationally-based”, the application of more
comprehensive decision-making procedures of an expli-
cit and transparent nature is required.
Developing alternative methodological approaches for
the evaluation of new medicines could therefore poten-
tially overcome such limitations, contributing to a more
complete framework for measuring value and making re-
source allocation decisions. Recently, the use of multiple
criteria decision analysis (MCDA) has appeared as a pos-
sible methodology to address current limitations of HTA
that result from traditional economic evaluation [6–13]. In-
deed, one of the conclusions of a recent systematic litera-
ture review on MCDA approaches applied in health care,
including HTA, was that decision-makers are positive about
the potential of MCDA to improve decision-making [14].
However limited studies have produced empirical evi-
dence from real world MCDA applications with the in-
volvement of stakeholders. In this paper we present a case
study as proof-of-concept, applying in practice a recently
developed MCDA methodological framework [15, 16]. A
decision conference workshop was organised with the par-
ticipation of a wide range of stakeholders for evaluating
and ranking a set of drugs for the treatment of metastatic
colorectal cancer (mCRC) following first line chemother-
apy. We adopted a facilitated decision analysis mod-
elling approach for expert panels [17]. Metastatic
colorectal cancer was chosen because of its high se-
verity, the availability of several expensive alternative
treatment options, and the fact that it has been the
topic of appraisals by several HTA agencies, includ-
ing to a number by the National Institute for Health
and Care Excellence (NICE) in England [18–23].
The methodological details of the case study are exten-
sively provided in the section below. The overall value
rankings of the different drugs are presented in the results
section, and the limitations of the study together with the
challenges encountered are described in the discussion.
Methods
Methodological process
An MCDA methodological process was adopted based on
Multi-Attribute Value Theory (MAVT) [24, 25] that com-
prises five distinct phases. These include (a) problem
structuring, (b) model building, (c) model assessment, (d)
model appraisal, and (e) development of action plans [15].
Further details are provided in the Appendix. A new value
framework, the Advance Value Framework, has been pro-
posed as part of which a generic value tree has been devel-
oped, incorporating different evaluation criteria for
assessing the value of new medicines and introducing a
set of MAVT modelling techniques for preference elicit-
ation and aggregation [16]. The new value framework was
tested in practice and was operationalised using a deci-
sion support software enabling the use of graphics to build
a model of values, facilitating both the design phases (a, b)
and the evaluation phases of the process (c, d) [26].
Clinical practice and scope of the exercise (problem
structuring)
This is a simulation exercise focusing on identifying and
assessing the overall value of second-line biological treat-
ments for mCRC following prior oxaliplatin-based (first
line) chemotherapy, by adopting the respective scope from
the latest Technology Appraisal (TA) of each technology
that has been appraised by NICE (at the time of study de-
sign and data collection, February 2015). As part of the
technology appraisal process of NICE, clinical and eco-
nomic evidence from a variety of sources is reviewed to
assess the technology’s health benefits (including impact
on quality of life and likely effects on mortality), the tech-
nology’s costs (focusing on costs to the NHS and personal
social services) and the technology’s relation of benefits to
costs, or “value-for-money” [27]. Therefore, it should be
highlighted that although the remit of NICE is to develop
recommendations on the appropriate use of new tech-
nologies within the NHS based on their clinical and cost
effectiveness, the aim of this exercise is different and
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relates to assessing a set of treatments for a common dis-
ease indication and ranking them based on their value by
considering additional types of evidence relating to their
benefit. The same or latest available clinical and economic
evidence from the corresponding TAs was used to popu-
late the performance of the alternative options across the
respective criteria attributes of our value tree, but in
addition supplementary evidence was used for value con-
cerns not addressed by NICE. The scope of TA242 was
adopted for the cases of bevacizumab, cetuximab and
panitumumab [21], whereas the scope of TA307 was
adopted for the case of aflibercept [22]. For the case of re-
gorafenib, no sufficient scope details existed in TA334 as
the appraisal was terminated early “because no evidence
submission was received” from the manufacturer [23], ex-
cluding it from the exercise. Further details on the scope
of the TAs including the alternative treatments com-
pared and their respective indications are provided in
the Appendix.
Adaptation of the Advance Value Tree for metastatic
colorectal cancer (model building)
Overall, we adopted a hybrid approach for the selection
of evaluation criteria [15] containing elements both from
the “value focused thinking” [28] and “alternative fo-
cused thinking” approaches [29].
A generic value tree offering an organised overview of
the various value concerns when evaluating new medi-
cines in an HTA context, the Advance Value Tree, has
been developed under the auspices of the Advance-HTA
project1 using a combination of literature reviews and
expert consultations [16, 30]. The aim was to identify all
the necessary criteria for assessing the value of new
medical technologies under a prescriptive decision-aid
approach and it was designed in a top-down "value-fo-
cused thinking" manner (criteria selected prior identify-
ing the alternative options) [15, 28], generating the
building blocks of a comprehensive value function. Ul-
timately, the resulting value tree is decomposed into five
value criteria clusters relating to i) the burden of disease
the technology addresses (BoD), ii) the technology’s
therapeutic impact (THE), iii) the technology’s safety
profile (SAF), iv) the overall innovation level (INN) and, v)
the wider socioeconomic impact (SOC):
Value ¼ f BoDþ THE þ SAF þ INN þ SOCð Þ ð1Þ
These five clusters of value dimensions were perceived
to comprise the critical aspects of value concerns to de-
cision makers for evaluating the value of new medicines
as part of HTA from a societal perspective [16], without
restricting “value” to the NHS. In addition to scientific
value judgments relating to therapeutic impact and
safety, the Advance Value Tree allows for the
incorporation of social value judgements which might be
of interest to key actors and stakeholders of different re-
gions, relating to burden of disease, innovation level and
socioeconomic impact, all of which can be captured and
measured explicitly.
The generic value tree was later adapted for the context
of mCRC in a bottom-up "alternative-focused thinking"
manner (criteria emerged following the comparison of the
alternative options) [15, 29]. This adaptation resulted in
the preliminary version of the mCRC-specific value tree
(Fig. 1). Overall, out of the five criteria clusters of the gen-
eric value tree, the burden of disease cluster was removed
because it was identical across the alternative treatment
options given that all of them were assessed for the same
indication (mCRC). The rest criteria clusters were decom-
posed into nine sub-criteria clusters with a total of 18 cri-
teria attributes. The list of attributes and their respective
definitions are shown in Table 1. In arriving at the mCRC-
specific attributes and the respective value tree, we strived
to adhere to key properties such as preferential independ-
ence and non-redundancy in order to ensure their selec-
tion is methodologically correct and theoretically robust
according to decision theory principles [31].
Evidence considered and alternative treatments
compared (model building)
The alternative treatment options compared in the exer-
cise included cetuximab monotherapy (Erbitux ®), panitu-
mumab monotherapy (Vectibix ®), and aflibercept (Zaltrap
®) in combination with FOLFIRI chemotherapy. Although
there is published evidence for the efficacy of cetuximab
in combination with chemotherapy, bevacizumab in com-
bination with non-oxaliplatin-based chemotherapy, and
regorafenib monotherapy as treatment options, we did not
include these treatments in the exercise because there was
absence of relevant clinical evidence submitted to NICE
as part of their respective TAs [21, 23].
Overall, evidence sources used to populate the prelim-
inary model included two randomised clinical trials
(RCTs) [32, 33], the respective NICE TAs [21, 22], the
NICE Evidence Review Group (ERG) reports [34] or any
related peer review publications [35, 36], summaries of
product characteristics (SPCs) available through EMA’s
European Public Assessment Reports [37–39] (or high-
lights of prescribing information leaflets), Anatomical
Therapeutic Chemical (ATC) classification system in-
dexes through the portal of the WHO Collaborating
Centre for Drug Statistics Methodology [40], and Clini-
calTrials.gov listings [41]. The sources of evidence used
for identifying the performance of the treatment options
across the criteria attributes are shown in Table 1. It
should be noted that among the two RCTs used for
populating the performance of the treatments across the
clinical attributes, one was a head to head trial directly
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comparing cetuximab versus panitumumab (ASPECCT
trial) [33] and the other one comparing aflibercept in
combination with FOLFIRI versus placebo with FOLFIRI
(VELOUR trial) [32]. More details on the clinical evi-
dence considered are provided in the Appendix.
Setting attribute ranges and reference levels (model
building)
As part of model building, we selected attribute ranges that
were encompassed within minimum (min) and maximum
(max) levels. Within the min-max attribute range we defined
“lower” (x_l) and “higher” (x_h) reference levels to act as
benchmarks for the preference value scores of 0 and 100 re-
spectively, needed for the construction of criteria value func-
tions and elicitation of relative weights (these are interval
scales and thus the importance of setting up clear bounds
for each attribute). Incorporation of such intermediate refer-
ence levels rather than extreme reference levels at the limits
of the value scale can protect against inaccuracies emerging
from potential non-linearity in value at scale’s limits [42]
and could ensure that the value scale has enough granularity
to distinguish the treatments. As a result, value scores could
possibly be negative or higher than 100 with v(xlower) = 0
and v(xhigher) = 100, essentially conducting a linear trans-
formation which is admissible to an interval scale such as a
value scale. The methodological basis for setting the
attribute ranges and reference levels is described in the
Appendix. A list of all attributes’ “lower” and “higher” ref-
erence levels together with their basis of selection, as
shaped before the workshop is provided in Table 2.
Decision conference (model assessment and appraisal)
The model assessment and model appraisal phases of the
exercise took place through a facilitated workshop with key
stakeholders and experts, taking the form of a decision con-
ference [43], organised by the authors and hosted at the
London School of Economics and Political Science (LSE)
on 30th of April 2015. Decision conference could be de-
fined as “a gathering of key players who wish to resolve im-
portant issues facing their organisation, assisted by an
impartial facilitator who is expert in decision analysis (DA),
using a model of relevant data and judgements created on-
the-spot to assist the group in thinking more clearly about
the issues” [44] (p.54); see also [17]. Typical stages of deci-
sion conference workshops include exploring the issues,
structuring and building the model, exploring the model
and agreeing on the way forward. In our study, the first two
stages were to a great extent informed by preparatory work
that had been conducted before the workshop, involving
extensive literature reviews.
Background material introducing the scope of the exer-
cise in more detail was sent to the participants one week
before the workshop. On the day of the workshop, the
model was presented to the participants and was revised
cluster by cluster in real time through a facilitated open dis-
cussion. It should be highlighted that the aim of the model
in such MCDA evaluation contexts is to act as an aid for
the group to interact and think about the decision prob-
lem constructively, rather than to provide the “correct” an-
swer [44, 45]. An iterative and interactive model-building
process was adopted, where debate was encouraged and
Fig. 1 Preliminary value tree for metastatic colorectal cancer (pre-workshop). Abbreviations: Contra. = Contraindications; MoA = Mechanism of
action; OS = Overall survival; HRQoL = Health related quality of life; PFS = Progression free survival; ORR = Objective response rate;
ATC = Anatomical therapeutic chemical; *Image produced using the Hiview software version 3.2.0.4
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differences of opinion actively sought. Generally, overall
agreement was reached in regards to criteria inclusion and
exclusion; in the few instances where this was unattainable,
criteria were left in the model for their impact to be tested
as part of the sensitivity analysis stage, where distinctive
viewpoints were finally resolved.
The composition of the group’s expertise and the num-
bers of the different stakeholders were decided based on
the structure of the past NICE committees responsible for
the appraisals of the alternative treatments [18, 20–22]. We
aimed to involve a small group between seven and 15 par-
ticipants; these group sizes have been shown to be sufficient
because they tend to preserve individuality while also
allowing efficient group processes to emerge, as they are
small enough to be able to work towards agreement, but
large enough to represent all major perspectives [46]. In
total, 13 participants were involved, their areas of expertise
and type of affiliation are shown in Table 3. More details
about the decision conference can be found in the
Appendix.
MCDA technique (model assessment and appraisal)
The selection of scoring, weighting and aggregating
techniques depends on the characteristics of the particu-
lar decision-making problem under consideration, as for
example the level of analytical precision required for the
Table 1 Attributes definition and sources of evidence
Cluster Attribute Definition Evidence source
Aflibercept +
FOLFIRI
Cetuximab Panitumumab
Therapeutic
Impact
Overall
survival
The median time from treatment randomisation to death Van Cutsem et al.
2012 [32]
Price et al. 2014
[33]
Price et al. 2014
HRQoL Health related quality of life using EQ-5D score TA 307 [22] Hoyle et al. 2013
[35]
Hoyle et al. 2013
Progression
free survival
The median survival time during which patients have not
experienced disease progression (using RECIST criteria)
Van Cutsem et al.
2012
Price et al. 2014
[33]
Price et al. 2014
Objective
response
rate
The proportion of patients that experience complete
response and partial response (using RECIST criteria)
Van Cutsem et al.
2012
Price et al. 2014 Price et al. 2014
Safety
Profile
Grade 3 AEs The proportion of patients experiencing a Grade 3 adverse
event
Van Cutsem et al.
2012
Price et al. 2014 Price et al. 2014
Grade 4 AEs The proportion of patients experiencing a Grade 4 adverse
event
Van Cutsem et al.
2012
Price et al. 2014 Price et al. 2014
Contra-
indications
The existence of any type of contraindication
accompanying the treatment
EPAR [39],
Prescribing info
EPAR [37],
Prescribing info
EPAR [38],
Prescribing info
Innovation
Level
ATC Level 1 The technology’s relative market entrance in regards to its
ATC Level 1 (Anatomical)
WHO ATC index
[40]
WHO ATC index WHO ATC index
ATC Level 2 The technology’s relative market entrance in regards to its
ATC Level 2 (Therapeutic)
WHO ATC index WHO ATC index WHO ATC index
ATC Level 3 The technology’s relative market entrance in regards to its
ATC Level 3 (Pharmacological)
WHO ATC index WHO ATC index WHO ATC index
ATC Level 4 The technology’s relative market entrance in regards to its
ATC Level 4 (Chemical)
WHO ATC index WHO ATC index WHO ATC index
ATC Level 5 The technology’s relative market entrance in regards to its
ATC Level 5 (Molecular)
WHO ATC index WHO ATC index WHO ATC index
Phase 1 The number of new indications for which the technology
is investigated in Phase 1 clinical trials
ClinicalTrials.gov
[41]
ClinicalTrials.gov ClinicalTrials.gov
Phase 2 The number of new indications for which the technology
is investigated in Phase 2 clinical trials
ClinicalTrials.gov ClinicalTrials.gov ClinicalTrials.gov
Phase 3 The number of new indications for which the technology
is investigated in Phase 3 clinical trials
ClinicalTrials.gov ClinicalTrials.gov ClinicalTrials.gov
Marketing
authorisation
The number of new indications for which the technology
has gained a marketing authorisation approval
ClinicalTrials.gov ClinicalTrials.gov ClinicalTrials.gov
Posology The frequency of doses in a given time period in
combination with the duration of the administration
EPAR,
Prescribing info
EPAR,
Prescribing info
EPAR,
Prescribing info
Socio-
economic
Impact
Medical
costs impact
The impact of the technology on direct medical costs
excluding the purchasing costs of the technology
BNF 69, TA 307,
Wade et al. 2013
[34]
BNF 69, TA 242
[21], Hoyle et al.
2013
BNF 69, TA 242,
Hoyle et al. 2013
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evaluation of the alternative interventions and the cognitive
burden expected to be posed to key actors and decision-
makers [13]. The pros and cons of different MCDA model-
ling techniques in health care evaluation and more precisely
on the decision-making process and outcomes generally re-
main unknown, therefore their selection represents an im-
portant area demanding further research.
Value preferences can be elicited using different question-
ing protocols. A value measurement method based on
pairwise qualitative comparisons is MACBETH (Measuring
Attractiveness by a Categorical Based Evaluation Technique),
an approach using qualitative judgments about the difference
of attractiveness between different pairs of attribute levels
[47, 48]. In this study we decided to test MACBETH because
of its strong theoretical foundations [49], numerous applica-
tions for real world problems [50, 51] and expected useful-
ness in HTA settings. As part of MACBETH, semantic
judgments made either by individuals or groups are
Table 2 Pre-workshop attribute reference levels and basis of selection
Cluster Attribute Metric Lower level Basis Higher level Basis
Therapeutic
Impact
Overall
survival
months 0 Minimum limit of the
scale
6.2 BSC
HRQoL utility score (EQ-5D) 0.6 Lower score used for
progressive state in TA307
[22]
0.75 BSC
Progression
free survival
months 0 Minimum limit of the
scale
1.9 BSC
Objective
response
rate
% of patients 0 Minimum limit of the
scale
11 FOLFIRI + Placebo (VELOUR trial)
[32]
Safety
Profile
Grade 3 AEs % of patients 68 10% higher than the
worst performing option
32 Median of BSC (AMGEN trial) [65]
and FOLFIRI + Placebo (VELOUR
trial)
Grade 4 AEs % of patients 24 10% higher than the
worst performing option
10 Median of BSC (AMGEN trial) and
FOLFIRI + Placebo (VELOUR trial)
Contra-
indications
types of contra-
indications
Lower
expected
benefit
and higher
expected
risk
Minimum limit of the
scale
Lower
expected
benefit
Median of options
Innovation
Level
ATC Level 1 relative market
entrance
5th Minimum limit of the
scale
4th Median of options
ATC Level 2 relative market
entrance
5th Minimum limit of the
scale
4th Median of options
ATC Level 3 relative market
entrance
5th Minimum limit of the
scale
3rd Median of options
ATC Level 4 relative market
entrance
5th Minimum limit of the
scale
1st Median of options
ATC Level 5 relative market
entrance
5th Minimum limit of the
scale
1st Median of options
Phase 1 number of new
indications
0 Minimum limit of the
scale
17 Median of options
Phase 2 number of new
indications
0 Minimum limit of the
scale
55 Median of options
Phase 3 number of new
indications
0 Minimum limit of the
scale
18 Median of options
Marketing
authorisation
number of new
indications
0 Minimum limit of the
scale
2 Median of options
Posology duration of
administration &
frequency of doses
Many hours,
every
2 weeks
Minimum limit of the
scale (worst performing
option)
Up to an
hour, every
2 weeks
Maximum limit of the scale (best
performing option)
Socio-
economic
Impact
Medical
costs impact
GBP (£) 7,086 10% higher than the
worst performing option
4,589 Median of options
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converted into a cardinal scale, providing a simple, construct-
ive and interactive approach with good prospects for facilitat-
ing the preference elicitation process of groups, such as in
technology appraisal committee settings.
We adopted the typical simple additive (i.e. linear aver-
age) aggregation approach, where the overall value V(.)
of an option a is given by the following Equation [52]:
V að Þ ¼
Xm
i¼1
wi vi að Þ ð2Þ
Where m is the number of criteria (attributes), and
wivi(a) the weighted partial value function of criterion i
for option a. This function V(.)_ is denominated a
multi-attribute value function [25].
We operationalised the methodology using M-
MACBETH [53], a decision support system based on
the MACBETH approach, to elicit the value preferences
of workshop participants and more precisely to build the
value tree, elicit value functions for the different attri-
butes, assign attribute relative weights through a qualita-
tive swing weighting approach, aggregate the preference
value scores and weights using an additive aggregation
(i.e. simple additive model) to derive overall weighted
preference value (WPV) scores, and conduct sensitivity
analysis [54]. Besides a consistency check between the
qualitative judgments expressed that is automatically
provided by the software, a second consistency check
was performed manually by the facilitator to ensure that
an interval scale is obtained, i.e. validate the cardinality
of the scale. This took place by comparing the sizes of
the intervals between the suggested scores and inviting
participants to adjust them if necessary [55], an essential
requirement for aggregation using simple additive value
models. More technical details on MACBETH are pro-
vided in the Appendix.
Costs calculation
Drug costs were calculated according to prices (excl.
VAT), pack sizes and dosage strengths as found in the
British National Formulary (BNF 69), and the recom-
mended dosage and treatment duration as reported in
the respective NICE technology appraisals [21, 22]. Vial
wastage was assumed in all calculations. Drug adminis-
tration costs for cetuximab and panitumumab were kept
consistent with Hoyle et al. [36] and administration costs
for aflibercept plus FOLFIRI consistent with the respect-
ive ERG Report [34].
Results
Criteria validation and amended value tree for metastatic
colorectal cancer
The final version of the value tree, as emerged following
the open discussion with the participants in the work-
shop is shown in Fig. 2. In total, nine out of the 18 attri-
butes were removed from the value tree because they
were judged from the participants to be non-
fundamental for the scope of the exercise, resulting in a
value tree of half its original size. Importantly, no criteria
were deemed to be missing. In the therapeutic impact
cluster, the Objective Response Rate (ORR) attribute was
removed. In the safety profile cluster, the contra-
indications attribute was removed and the Grade 3 Ad-
verse Events (AEs) and Grade 4 AEs attributes were pro-
posed to be aggregated into a single attribute; however
this aggregation required a significant modelling iter-
ation, and due to time constraints it was decided to ex-
clude the Grade 3 AEs attribute and only include Grade
4 AEs for the purpose of the simulation exercise. In
terms of the innovation cluster, participants had mixed
views. Consensus was reached for the ATC Level (L)5,
Phase 1 and Phase 2 attributes to be removed, and for
the ATC L4 to be included as a binary variable (i.e. first
entrance in the chemical class vs. second or subsequent
entrance in the chemical class); however strong disagree-
ment existed on whether to include Phase 3 and Market-
ing Authorisation attributes, with half the participants in
favour of and half the participants against their inclu-
sion. As a result, both of the attributes were left in the
model and their impact was then tested at the end of the
workshop as part of the sensitivity analysis stage.
Validation of attribute ranges and reference levels
Another important amendment in the model included a
change in the definitions of the “lower” and “higher” ref-
erence levels, which define the 0 and 100 scores in the
value functions and act as anchors for swing weighting.
For the case of clinical attributes (i.e. therapeutic impact
Table 3 List of decision conference participants
Participant Expertise Affiliation
1 Medical oncologist - CRC expert NHS Trust/Teaching
hospital
2 Medical oncologist - CRC expert NHS Trust
3 Consultant - community
paediatrician
NHS Trust/HTA agency
4 Public health expert Academia
5 Pharmacist Independent
6 Health economist Academia
7 HTA expert Academia
8 Health economist Academia
9 HTA expert Academia
10 Medical statistician Academia
11 Patient Independent
12 Patient carer Independent
13 Patient advocate Charity
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and safety profile attributes), a consensus was reached
by the group that the “lower reference” level should ac-
tually correspond to the “satisfactory performance”
(proxied by Best Supportive Care, BSC) rather than the
“worst performance” plausible. As a result, the “lower
reference” level was switched to the previously defined
“higher reference” level (i.e. satisfactory performance),
and the “higher reference” level was set equal to the
maximum level. The newly-defined attribute levels were
therefore: i) the “lower reference” level (i.e. BSC-based sat-
isfactory performance); the “higher reference” level (equal
to the maximum, best performance plausible, level), and the
minimum level (i.e. worst performance plausible). In doing
so, the amended “lower” and “higher” reference levels were
now corresponding to “satisfactory performance” (proxied
by BSC) and “best performance” respectively, with options
performing worse than the “satisfactory” level getting a
negative score, and all options obtaining less than 100 score.
As a consequence, a similar change was introduced for
the case of - now single - safety profile attribute (Grade 4
AEs), with the “lower reference” level being defined based
on “satisfactory performance”, the “higher reference” level
based on “best performance” (i.e. minimum limit of the
scale) and the minimum level remaining the same.
For the case of innovation attributes, the “higher refer-
ence” levels were set equal to the “best performance”
levels, with the “lower reference” levels remaining the same
(equal to the worst performance). Similarly, for the case of
the socioeconomic impact attribute (impact on direct med-
ical costs) the “higher reference” level was also set equal to
the “best performance” level, with the “lower reference”
level remaining the same (equal to the worst performance).
The arising changes in the attribute reference level
definitions, before and after the workshop for each of
the criteria clusters are shown in Fig. 3, and the final list
of attributes’ “lower” and “higher” reference levels, to-
gether with their basis of selection are provided in Table 4.
Options performance, criteria weights and overall
preference value rankings
Two examples of value judgements matrices and their
conversion into a linear and non-linear value function for
Fig. 2 Final Value Tree for metastatic colorectal cancer (post-workshop). * Image produced using the M-MACBETH (beta) software version 3.0.0
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the case of the Overall Survival (OS) and Health Related
Quality of Life (HRQoL, measured by the EQ-5D score)
attributes respectively are shown in the Appendix.
The performance of the options across the different
attributes together with the “lower” and “higher” refer-
ence levels are shown in Table 5. The different columns
correspond to the performance of the different options
(including the two reference levels), across the respective
attributes shown in the rows. The overall WPV scores
for all options across the different attributes, together
with the respective attribute baseline weights are shown
in Table 6; similarly to Table 5, the different columns
correspond to the preference value scores of the differ-
ent options (including the two reference levels), across
the respective attributes shown in the rows. Cetuximab
scored the highest overall WPV score of 45.7, followed
Fig. 3 Changes in the definitions of the attribute reference levels, pre- and post- workshop
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by panitumumab with an overall WPV score of 42.3.
Aflibercept in combination with FOLFIRI was ranked
last with an overall WPV score of 14.4, partially due to
its performance on Grade 4 AEs (21%) which lied below
the lower reference level of the value scale (10%), produ-
cing an absolute preference value score of −117.9 and a
weighted preference value score of −27.4. A stacked bar
plot of the WPV scores of the alternative treatments
across the attributes is shown in Fig. 4.
The relative weights assigned to the different attributes
are shown in Fig. 5. The criteria are ranked based on
their relative magnitude, ranging from relatively more
important criteria to relatively less important criteria
(from left to right across the x-axis), taking into account
the “lower” – “higher” ranges of the attributes. The OS
and Grade 4 AEs attributes were assigned a relative
weight totaling more than the relative weights of all
other attributes together, i.e. 52%. Out of 100, the thera-
peutic impact cluster (three attributes) totaled overall a
relative weight of 47, the safety profile cluster (single at-
tribute only) a relative weight of 23, the innovation level
cluster (four attributes) a relative weight of 19, and the
socioeconomic impact cluster (single attribute only) a
relative weight of 12.
Table 4 Post-workshop attribute reference levels and basis of selection
Cluster Attribute Metric Lower level Basis Higher level Basis
Therapeutic
Impact
Overall
survival
months 6.2 BSC 14.9 10% higher than the best
performing option
HRQoL utility score (EQ-5D) 0.75 BSC 0.9 10% higher than the best
performing option/ general
population
Progression
free survival
months 1.9 BSC 7.6 10% higher than the best
performing option
Safety
Profile
Grade 4 AEs % of patients 10 Median of BSC arm from AMGEN
trial and placebo + FOLFIRI arm
from VELOUR trial
0 Maximum limit of the scale
Innovation
Level
ATC Level 4 relative market
entrance
≥2nd Minimum limit of the scale, binary
variable
1st Maximum limit of the scale,
binary variable
Phase 3 number of new
indications
0 Minimum limit of the scale 21 10% higher than the best
performing option
Marketing
authorisation
number of new
indications
0 Minimum limit of the scale 3 10% higher than the best
performing option
Posology duration of
administration &
frequency of doses
Many hours,
every two
weeks
Minimum limit of the scale (worst
performing option)
Up to an
hour, every
two weeks
Maximum limit of the scale
(best performing option)
Socio-
economic
Impact
Medical
costs impact
GBP (£) 7,086 10% higher than the worst
performing option
0 BSC
Table 5 Options performance across the criteria attributes
Attribute Metric Lower level Aflibercept +
FOLFIRI
Cetuximab Panitumumab Higher level
Overall survival months 6.2 13.5 10 10.4 14.9
HRQoL utility (EQ-5D) 0.75 0.78 0.78 0.78 0.9
Progression free
survival
months 1.9 6.9 4.1 4.4 7.6
Grade 4 AEs % of patients 10 21 5 7 0
ATC L4 relative market
entrance
2nd 1st 1st 2nd 1st
Phase 3 # of new indications 0 18 19 7 21
Marketing
Authorisation
# of new indications 0 3 1 0 3
Posology duration & frequency hours, every
2 weeks
hours, every
2 weeks
1 hour, every
week
≤1 hour, every
2 weeks
≤1 hour, every
2 weeks
Medical costs impact GBP (£) 7,086 6,738 4,589 1,940 0
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Value for money analysis
By incorporating the total purchasing costs of the differ-
ent drugs (including their administration costs), their
overall WPV scores versus their costs can be plotted,
taking the form of an MCDA cost-benefit plane (Fig. 6).
Using purchasing costs of treatments separately to their
overall value scores is based on the rationale that only
attributes of benefit should act as criteria in multi-
criteria models [56]. However, a treatment’s impact (i.e.
net effect) on resources, ranging from medical related to
productivity gain, is usually an important value concern
for decision-makers and could therefore act as a relevant
objective or criterion in the analysis. For this reason,
“impact on costs” in relation to a relevant benchmark
comparator rather than absolute costs could be consid-
ered as part of the valuation, being exclusive of the pur-
chasing costs of the drugs themselves which could then
be used as the cost component to calculate an MCDA
cost-benefit metric in tandem to their value scores [16].
By using rounded up total cost figures of £18,000 for
cetuximab (£12,824 drug cost and £5,191 administration
cost), £27,000 for panitumumab (£23,643 drug cost and
£3,374 administration cost), and £29,400 for aflibercept in
combination with FOLFIRI (£17,750 drug cost and
£11,630 administration cost), and dividing them with over-
all WPV scores, their costs per MCDA value unit were cal-
culated to be £394, £638, and £2,046 respectively (Table 6).
Assuming the use of a common treatment compara-
tor, the incremental cost value ratio (ICVR) of the
different health care interventions could be estimated,
a form of an MCDA cost-benefit ratio. Therefore, in
terms of value-for-money, aflibercept in combination
with FOLFIRI is shown to be dominated by panitu-
mumab, both of which are shown to be dominated by
cetuximab which is associated with the highest overall
WPV score and the lowest cost.
Table 6 Overall weighted preference value (WPV) scores, individual preference value scores, relative weights, costs and cost per unit
of value
Lower level Aflibercept + FOLFIRI Cetuximab Panitumumab Higher Level Relative Weights
Overall WPV score 0.0 14.4 45.7 42.3 100.0 100
Overall survival 0.0 83.9 44.4 48.9 100.0 29
HRQoL 0.0 15.0 15.0 15.0 100.0 13
Progression free survival 0.0 90.3 51.4 55.6 100.0 5
Grade 4 AEs 0.0 −117.9 50.0 30.0 100.0 23
ATC L4 0.0 100.0 100.0 0.0 100.0 6
Phase 3 0.0 50.0 66.7 19.4 100.0 2
Marketing Authorisation 0.0 100.0 30.0 0.0 100.0 3
Posology 0.0 0.0 37.5 100.0 100.0 7
Medical costs impact 0.0 7.0 50.0 78.9 100.0 12
Costs (£) 29,400 18,000 27,000
Cost per unit of value 2,046 394 638
Fig. 4 Stacked bar plot of treatments’ individual weighted preference value (WPV) scores across all attributes. Abbreviations: HRQoL = Health
related quality of life; AE = Adverse Event; ATC L4 = Anatomical therapeutic chemical level 4
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NICE’s conclusion about the three technologies was
that none of them should be recommended for use
within NHS because they either do not represent a cost-
effective use of NHS resources (for the case of cetuxi-
mab and panitumumab monotherapies) [21], or because
of significant uncertainty around the extrapolation of
overall survival and a higher than normally acceptable
maximum incremental cost effectiveness ratio (ICER)
range (for the case of aflibercept in combination with
chemotherapy) [22]. Interestingly, if the efficiency rank-
ings of the three treatments based on their ICERs (i.e.
incremental cost per QALY) were to be compared versus
their respective rankings based on their cost per MCDA
value unit, a difference would be observed as aflibercept
in combination with FOLFIRI produced the lowest ICER
(£51,000) [22], followed by cetuximab (around £90,000) and
then by panitumumab (>£110,000) [21]. This discrepancy in
efficiency rankings according to which aflibercept in com-
bination with FOLFIRI came up third rather than first could
partially be explained due to the relatively low value score
of the treatment in regards to Grade 4 AEs (−118) in com-
bination with its relatively large weight (0.23) which could
however be perceived as a study limitation (see the discus-
sion under the Limitations and challenges section).
Sensitivity and robustness analysis
Deterministic sensitivity analysis was conducted to
address parameter uncertainty by exploring the impact
of baseline weight changes on the ranking of the options
(figures shown in the Appendix). In order for panitumumab
to become better ranked than cetuximab any of the follow-
ing changes in baseline weights would be needed: OS from
28.9 to 59.8, PFS from 4.8 to 47.7, Grade 4 AEs from 23.3
to 7.5, ATC L4 from 5.8 to 2.5, Posology from 7 to 11.8, or
Medical costs impact from 11.6 to 21.0. Similarly, for afli-
bercept plus FOLFIRI to become better ranked than cetuxi-
mab any of the following changes in baseline weights
would be needed: OS from 28.9 to 60.3, PFS from 4.8 to
47.3, Grade 4 AEs from 23.3 to 5.6, or Marketing Author-
isation from 3.5 to 33.3. Finally, for aflibercept plus FOL-
FIRI to become better ranked than panitumumab any of
the following changes in baseline weights would be needed:
OS from 28.9 to 60.4, PFS from 4.8 to 47.2, Grade 4 AEs
from 23.3 to 5.4, ATC L4 from 5.8 to 26.4, Phase 3 from
2.3 to 49.0, or Marketing Authorisation from 3.5 to 24.6.
Therefore, conclusions were fairly robust as treatment
rankings were not influenced by changes of 50% or less on
any of the baseline normalised weights, the most sensitive
Fig. 5 Criteria weights histogram. Abbreviations: AE = Adverse Event; HRQoL = Health related quality of life; ATC L4 = Anatomical therapeutic
chemical level 4
Fig. 6 Cost benefit plot of overall weighted preference value
(WPV) scores versus costs. Abbreviations: CET = cetuximab;
PAN = Panitumumab; AFLI = Aflibercept (plus FOLFIRI). * Image
produced using the M-MACBETH (beta) software version 3.0.0
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attributes being Posology and Medical costs impact attri-
butes on the cetuximab versus panitumumab comparison
(requiring a 69% and 81% change respectively for panitu-
mumab to become better ranked), with changes of at least
up to 100% on the remaining baseline normalised weights
exerting no impact on the results.
The robustness of the results was also tested by conduct-
ing 8-way sensitivity analysis in the reference levels of the at-
tributes using the respective function of the M-MACBETH
software (“Robustness analysis”), which showed that a
simultaneous change of up to 5 value points across all of
the attribute reference levels would not impact the ranking
of the alternative treatments (figure in the Appendix).
However other types of uncertainty might exist, such as
stochastic uncertainty, structural uncertainty and hetero-
geneity, which could be addressed through more advanced
statistical approaches, including probabilistic sensitivity
analyses, Bayesian frameworks, fuzzy set theory or grey
theory [57]. For example, uncertainty associated with the
performance of the options due to sampling variation of
clinical studies, or with the criteria weights due to inability
to derive or agree on weights, might make the application
of point estimates inappropriate in which case stochastic
multi-criteria acceptability analysis (SMAA) might be
preferred [58].
Discussion
This simulation exercise adopts an MCDA methodo-
logical process for the context of HTA [15] and tests a
newly developed value framework (Advance Value Frame-
work) in practice through a decision conference approach
[52]. The methodological process we adopted is generally
in alignment with recent good practice guidelines on the
use of MCDA for health care decision-making, in respect
to design, implementation and review of the analysis [13].
Overall, a set of different treatment options for the in-
dication of mCRC at second-line were assessed and
ranked based on their overall WPV scores. These scores
acted as value metrics or value indexes, comprised of
the performance of the alternative treatment options
against an explicit set of criteria while adjusting for the
relative importance of these criteria, as reflected by the
preferences of the group. Finally, incorporation of drug
costs (purchasing and administration costs) enabled the
production of “cost per unit of value” ratio estimates
while revealing the dominance of one treatment. Assum-
ing that the participants of the workshop formed a com-
mittee group responsible for choosing or recommending
the funding of one of the three alternative options as
part of a one-off decision, this treatment could be a ra-
tional choice for the group assuming that the respective
budget needed is available. It should be clear that the de-
cision context considered and problem scope addressed
by this study is not in line with the current NICE remit,
which is that of repeated decisions, as part of which an
intervention is evaluated in terms of whether it provides
good value for money given the opportunity cost to in-
vest in other interventions across different disease areas.
Therefore, while in this exercise the top-ranked option
would be recommended, in the case of NICE it might be
the case that none of the options is recommended unless
they represent an efficient allocation of resources across
the total NHS budget.
Strengths and opportunities
Among the biggest benefits of the methodology adopted
as reflected through this particular experimental applica-
tion are the explicit incorporation of multiple benefit di-
mensions, some of which are possibly hard-to-measure
but proved important nevertheless and the elicitation of
value trade-offs between them. A more detailed discus-
sion around the advantages of the value framework from
a decision-making perspective is described in the section
below (Practice and policy implications).
A central strength of the methodology as experienced
through this case study is the development of the evalu-
ation model with a group of relevant stakeholders
(health care professionals, methodology experts, pa-
tients), which proved to be essential for creating a
shared understanding of what constitutes value in this
decision context. This was evident across all its phases,
ranging from model-building to model appraisal, play-
ing a profound role across all the stages.
Starting with criteria selection, by sharing participants’
views and opinions among the group while seeking a
consensus approach, the original version of the value
tree and its criteria were validated, amending its contents
and leading to the exclusion of some attributes that
seemed non-fundamental or irrelevant. For example Ob-
jective Response Rate (ORR), the sum (i.e. proportion) of
patients that experience complete response and partial re-
sponse (using the RECIST criteria), which was originally
included in the value tree was decided to be removed
because of irrelevance. Initially, the clinical view was raised
that stable cancer (i.e. non-responding) might be just as
good of an outcome as tumour shrinking. Although the
argument was expressed that in theory ORR could help
into controlling symptoms better, there is no firm evidence
for this in the literature. The HRQoL and Grade 4 AEs
measures are instruments designed for the assessment of
symptoms and ORR gives no additional value. Thus, its
inclusion in this regard would even entail double counting
effects. In turn, it was suggested that ORR is primarily de-
signed for measuring patient response and treatment effi-
cacy under the settings of new drug development and not
a major guide to clinical practice in the setting of advanced
disease. With regard to clinical practice, the use of PFS as
a metric could be perceived more complete and reflective.
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During model assessment and the elicitation of prefer-
ences through value functions, the structured discussion
as facilitated by one of the authors enabled the represen-
tation of all the different perspectives for the purpose of
valuation. Although occasionally some of the partici-
pants might at first have had opposing views and beliefs
in regards to their preference judgments, in most of the
cases these conflicts were terminated or defused following
extensive discussions. An example would be the elicitation
of the Overall Survival (OS) value function which started
with contrasting perspectives on how to assess additional
months of life, but following far-reaching dialogues
around the added value of different life increments, an
agreement was established that each additional month of
life was associated with an equal magnitude of value, as
revealed through a linear value function.
The systematic assessment of all types of evidence
together enabled the identification of strengths and
weaknesses for each treatment, which in turn could
be used to influence their use under clinical practice,
or even support their design and improvement as part
of the clinical development process. For example,
although aflibercept in combination with FOLFIRI
(afli + FOL) was associated with the highest score in
OS, overall it ranked last, partially because of a highly
negative score in Grade 4 AEs (for more information
see below the Limitations and challenges section).
Assuming that such an analysis and discussion were
conducted at an earlier stage of the product’s life
cycle, for example during Phase 2 clinical trials, these
insights could possibly influence future aspects of
clinical development by inducing changes into lead
design and drug formulation with the view to en-
hance the envisaged performance characteristics per-
ceived to be outranked or disadvantaged.
Another benefit of the evaluation we conducted was a
clear separation between the performance of the treat-
ments and their valuation, based respectively on the
availability of evidence across the attributes and the es-
tablishment of value increments within criteria and value
trade-offs across criteria, with the latter being amenable
to sensitivity analysis. The explicit modelling of prefer-
ences and values represented how much the group val-
ued incremental performances in each attribute, as well
as their priorities for the different criteria, represented
by the weights. This separation allowed us to assess the
robustness of results for preferences variations. For
example, sensitivity analysis at the end of the workshop
in respect to the baseline weights of the innovation attri-
butes, for which some of the participants did not fully
agree with their elicited relative importance, assured the
authors and the participants that the ranking of the
treatments was not sensitive to minor variations along
their range (last column of Table 6).
Limitations and challenges
Results should be interpreted with caution. It should be
clear that this is a simulation exercise illustrating the
application of a new value framework in practice with
the results produced not intended to inform policy
making in this instance. For this to occur, the clinical
evidence used to inform the performance of the treat-
ments across the Therapeutic Impact and Safety Profile
clusters should ideally come from head to head clinical
trials directly comparing all treatment of interest. Alter-
natively, relative treatment effects should be estimated
through indirect treatment comparisons making use of
indirect evidence through a common comparator, or
network meta-analysis such as mixed treatment com-
parisons making use of all available evidence, both dir-
ect and indirect [59]. Instead, a limitation in this study
is that we used un-synthesised clinical evidence coming
from different clinical trials which did not have a com-
mon comparator: a head to head clinical trial directly
comparing two of the three treatments (ASPECCT trial
for cetuximab vs panitumumab) and another clinical
trial comparing the third treatment with placebo
(VELOUR trial investigating aflibercept with FOLFIRI
vs placebo with FOLFIRI). In real world evaluations
aiming to inform policy-making, an evidence synthesis
step should be conducted together with evidence col-
lection as part of the model building phase. An example
would be the application of an SMAA approach for
assessing the comparative benefit-risk of different
statins for use in primary prevention [60], which used
comparative effects based on evidence that had been ori-
ginally collected as part of three meta-analyses [61–63], or
the combination of SMAA with a network meta-analysis
for assessing the comparative benefit-risk of second-
generation antidepressants and placebo [64].
Among one of the main challenges was setting the
“higher” and “lower” reference levels on each attribute,
based on which treatment scores were derived. For
example, as described above, in the case of Grade 4
AEs, a “higher” reference level was set equal to the
minimum natural limit of the scale (i.e. 0%) that was
regarded as an “ideal” level. However, this level could
be perceived as extremely optimistic, or “too good to be
true”. Possibly more important though in terms of
Grade 4 AEs attribute’s impact on the scoring of the
alternative treatments was the definition of the “lower”
reference level as this influenced the negative partial
value score observed for one of the treatments and con-
sequently its overall WPV score. The lower reference
level of 10% adopted was regarded as “satisfactory” per-
formance and was derived using the median of the BSC
comparator arm of panitumumab’s pivotal clinical trial
(AMGEN trial) [65], and the placebo plus FOLFIRI
comparator arm of aflibercept’s pivotal clinical trial
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(VELOUR) [32]. As a result, aflibercept in combination
with FOLFIRI produced a negative partial value score
in Grade 4 AEs because its performance was less pre-
ferred than the lower reference level. Although we tried to
be as objective as possible when setting the reference
levels, others might have ended up with different anchor
points. However such expected differences most probably
would have been of a minor impact, without necessarily
affecting the overall valuation of the treatments. The final
reference levels adopted were decided following the feed-
back we received during the workshop. Liaising with a
range of experts during the model-building phase for en-
suring the choice of relevant reference levels, before the
elicitation of preferences and the model assessment phase,
seems to be a necessary step for ensuring good practice
and robust results.
Another challenge related to the use of the EQ-5D
instrument to measure HRQoL (given the lack of
other relevant evidence), which is associated with two
issues. Firstly, by definition it is an aggregate measure
so it does not allow to make value trade-offs among
its different dimensions, and, secondly, it already cap-
tures the preferences of the general public so the use
of unweighted health states might be more appropri-
ate. Therefore, it should be acknowledged that MCDA
does not act as a panacea for challenges relating to
appropriate evidence collection on patient experience
but mainly as a tool to understand, construct and
analyse their preferences on already existing evidence.
Another issue would be the evaluation of clusters
where participants have less experience or knowledge.
For example, during the evaluation of the HRQoL attri-
bute, some of the participants had difficulties in
comprehending the differences in value between the
different EQ-5D index scores. However, feedback from
clinicians and patients helped the rest of the group to
understand the relative differences across health states
so that they could express their preferences. Although
such an input proved crucial and, to a large extent, sat-
isfactory to the information prerequisites of the group,
it would be advantageous if the EQ-5D index scores
were accompanied with qualitative descriptions to illus-
trate the impact to patients’ quality of life.
An additional limitation would relate to the tech-
nical difficulties associated with ensuring that all attri-
butes possess the required theoretical properties for a
multi-criteria evaluation, as for example that they are
preference independent if used in additive models
such as the current one; alternatively, attributes might
have to be combined together or multiplicative
models might have to be used instead. Furthermore,
although in the present case study only the HRQoL of
the stable disease state is assessed, mainly because
none of the treatments is assumed to have any effects
during the progressive disease state [22, 36], in other
diseases this might not hold true.
Practice and policy implications
Implementation of MCDA methodologies and their link-
age to policy-making could take place in the form a sup-
plementary “incremental” mode to cost-effectiveness
analysis (CEA) adjusting the ICER through the incorpor-
ation of additional benefit dimensions, or in the form
of a pure “clean-slate” mode where value is derived
de novo (i.e. from the beginning) without the use of
CEA [7, 15].
Both approaches are associated with different pros
and cons and as a result the choice between the two
should be made depending on the decision context of
interest, while taking into account the current evalu-
ation guidelines in place and the flexibility of the
decision-makers. For example, the application of an
MCDA approach in alignment with a supplementary or
“incremental” mode might enable an easier exploration
and implementation by decision-makers in real-world
settings. Assuming the proposed methodological
process is adhered to, as part of a pure or “clean-slate”
approach for use in HTA, the application of the
Advance Value Framework presents a number of poten-
tial advantages to decision-makers in the context of
HTA and the wider context of Value Based Assessment
compared with currently used HTA approaches such as
economic evaluation techniques.
Firstly, it acts as an instrument of more complete
value assessment leading to improved comprehensive-
ness given the explicit incorporation of multiple criteria
and construction of value judgements on the perform-
ance of alternative options that can help decision-
makers to construct their overall value concerns.
Secondly, assignment of quantitative criteria weights
can reflect differences in the relative importance of the
evaluation criteria, enabling decision-makers to realise
the value trade-offs they are willing to make and there-
fore construct and analyse their own value preferences.
Thirdly, the methodological process can be informed
through extensive expert engagement and direct stake-
holder participation leading to an encompassing capture
of value perceptions and value preferences. Fourthly, it
provides flexibility given that the details and technical
characteristics of the different methodological stages can
be adapted to accommodate particular decision-makers’
needs. Finally, the entire process is fully transparent,
allowing to illustrate the rationale behind the decision out-
comes which could enable them to become more credible
and well-accepted from the wider stakeholder community
and society.
The resulting overall WPV scores derived from the
MCDA process can act as a more encompassing
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measure of value given that multiple benefit dimen-
sions are explicitly assessed and therefore could be
used to drive the coverage decision and pricing nego-
tiations of new medicines and health care interven-
tions in a more comprehensive manner. Consideration
of purchasing costs in parallel with the overall value
of the alternatives options can then be used to esti-
mate the incremental cost value ratio (ICVR) of the
different health care interventions. Dividing costs by
benefits reflect the associated opportunity cost, help-
ing to obtain the best value-for-money alternatives
and contribute to efficient priority setting and
resource allocation [44]. For example, assuming the
existence of a defined budget constraint for funding a
set of alternative treatments, the most efficient
options could be allocated based on their ICVR rank-
ings, from the lowest (cost-benefit) ratio to the high-
est ratio, until the available budget is exhausted [66].
Incorporation of budget impact considerations in the
cost-value ratio estimates at system level could take
place by taking into account the number of patients
that will receive the treatment, however benefits and
costs should be estimated in comparable units so that
the results are not biased towards the cheapest alter-
native, as for example on a per-patient basis [13].
In this context, the case study conducted aimed to
assess and rank alternative treatment options for the
same disease indication. A number of disease-specific
clinical endpoints were incorporated as evaluation cri-
teria which reflected a number of common value con-
cerns relating to the particular intra-indication decision
context of interest. Given the early and experimental
stage of this methodology, further testing applications
could target relatively expensive health care interven-
tions for disease indications with high unmet need, or
long term treatments for chronic conditions where
multiple alternative options exist, essentially investigat-
ing coverage decisions where multiple benefits and/or
high budget impact might be at stake.
Such an attempt at a broader inter-indication level,
aiming to assess the value of alternative treatments
across different disease indications might be more
challenging as it would need to ensure the use of a
common value model (in terms of attributes, value
functions and relative weights) that adequately
addresses the value concerns for the alternative treat-
ments across diseases with different characteristics. In
such an evaluation context, criteria and attributes
might need to become more generic and less disease-
specific, using health benefit metrics such as the
QALY, which allow for the comparison of health gain
across different patient populations. Therefore, analyt-
ical trade-offs might have to take place between the
potential sensitivity in “picking-up” value through
disease-specific health outcomes and the practicality
of comparing value across patients through common
criteria of generic health outcomes.
Another challenge would relate to designing an effi-
ciency frontier or threshold (i.e. cut-off point) across dis-
eases, essentially an alternative to the current ICER
threshold. This issue would not be limited to the appli-
cation of MCDA and would face all the theoretical and
practical hurdles associated with the estimation of a
sound cost-benefit threshold based on opportunity cost
that have been seen to date [67, 68].
The preference elicitation process could be adjusted
so that value preferences are not restricted to the
appraisal committee or evaluation board responsible
for decision-making. Instead, evidence on the prefer-
ences of the wider stakeholder community could be
potentially incorporated in the evaluation, as for ex-
ample by conducting discrete choice experiment stud-
ies to identify relative criteria importance in the form
of weights, as in the case of societal preferences of
citizens in Belgium [69].
Conclusion
The challenge to assess novel treatments and therapeutic
combinations in a setting of significant budgetary pres-
sure on health services require novel methodologies of
assessment allowing the incorporation of preferences
from groups of stakeholders across a set of multiple
value dimensions. In this study we described an inte-
grated multi-criteria approach simulating an HTA
context for the case of advanced colorectal cancer treat-
ments. Innovative approaches to decision-making for
pricing and reimbursement of new therapies will be
essential in the coming era of precision medicine and
expensive but effective immunotherapies for cancer. Ul-
timately, because of their characteristics enabling a
structured process, MCDA methodologies such as the
Advance Value Framework could overall facilitate HTA
decision-making acting as a reasonable resource alloca-
tion tool that, among others, incorporates a more holis-
tic and transparent approach to value assessment and
value communication. Future research could test the
Advance Value Framework methodology by conducting
similar case studies with multi-stakeholder groups in
different countries.
Endnotes
1Advance-HTA was a research project funded by the
European Commission’s Research Framework Programme
(FP7). It comprised several complementary streams of
research that aimed to advance and strengthen the meth-
odological tools and practices relating to the application
and implementation of Health Technology Assessment
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(HTA). It was a partnership of 13 Consortium members
led by the London School of Economics - LSE Health.
2No evidence were submitted to NICE for cetuximab
in combination with chemotherapy, therefore this com-
bination fell outside the scope of our exercise too.
Appendix
Methodological process
At first, as part of the problem structuring phase, the
decision problem and the aims of the analysis are
defined, and the relevant decision-makers and other
key stakeholders are identified. Next, as part of the
model-building phase, objectives and/or relevant cri-
teria are identified in order to reflect decision makers’
goals and areas of concern, and attributes are selected
to operationalise the criteria. In addition, under the
same phase, selection of the alternative options takes
place and evidence on their performance across the
selected criteria is identified. Following that, under
the model assessment phase, the performance of op-
tions against the criteria is assessed (i.e. scoring) and
criteria are weighted according to their relative im-
portance (i.e. weighting). Subsequently, as part of the
appraisal phase, scores and weights are combined in
order to produce overall WPV scores, taking the form
of a value index (i.e. aggregation). In combination
with sensitivity analysis, the results are examined and
their robustness is determined. Finally, as part of
action planning, the outcome of the analysis can be
used to inform resource allocation decisions, of a
coverage or pricing nature.
Clinical practice and scope of the exercise (problem
structuring)
The TA242 scoping evaluated bevacizumab in combin-
ation with non-oxaliplatin chemotherapy, cetuximab
monotherapy or combination with chemotherapy, and
panitumumab monotherapy for mCRC after first-line
chemotherapy. The populations covered for the case of
cetuximab and panitumumab were mCRC patients
expressing the wild-type (i.e. non-mutated) form of the
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
(KRAS) gene, because these agents, which target the epi-
dermal growth factor receptor (EGFR), have been shown
to be ineffective for treatment of tumours expressing the
mutated KRAS gene [70–72]. KRAS expression does not
impact on the case of bevacizumab. Bevacizumab was
appraised only when in combination with non-oxalipla-
tin based chemotherapy, because under UK clinical prac-
tice oxaliplatin containing combinations (i.e. FOLFOX)
are generally used in the first line. Once cancers demon-
strate resistance to FOLFOX patients are then eligible
for non-oxaliplatin based chemotherapy regimens such
as FOLFIRI (irinotecan, 5-fluorouracil and folinic acid),
therefore, patients treated with bevacizumab at second-
line would normally receive it in combination with non-
oxaliplatin based chemotherapies. Hence, the exclusion
of oxaliplatin based chemotherapies from the scope of
the TA and our exercise.
The scope of TA307 specified the evaluation of afliber-
cept in combination with FOLFIRI that has progressed
following prior oxaliplatin based chemotherapy. Again,
the scope of the TA and our exercise considered afliber-
cept only in combination with non-oxaliplatin chemo-
therapy for the same reason explained above.
Evidence considered and alternative treatments
compared (model building)
As part of TA242, for the case of cetuximab and
panitumumab, NICE considered clinical evidence
coming from two open label, Phase 3 RCTs respect-
ively; the first one investigating the use of cetuximab
plus best supportive care (BSC) compared to BSC
alone (CO.17 trial)2 [73] and the second one investi-
gating the use of panitumumab plus BSC compared
to BSC alone (AMGEN trial) [65], in patients with
chemotherapy-refractory mCRC. For the case of beva-
cizumab, as part of TA242, only one RCT had been
identified investigating bevacizumab as a second line
treatment (E3200 trial) [74]. However in that trial,
bevacizumab was administered in combination with
an oxaliplatin-containing chemotherapy which was
outside the appraisal’s scope, and hence outside the
scope of our analysis.
As part of TA307, the clinical evidence for aflibercept
was taken from a prospective multinational, randomized,
double-blind, parallel-arm, phase 3 study investigating
the addition of aflibercept to FOLFIRI in patients with
mCRC previously treated with an oxaliplatin-based regi-
men (VELOUR trial) [32].
Finally, for the case of regorafenib, no clinical evidence
was considered as part of TA334 because no evidence
submission was received from the manufacturer and the
appraisal was terminated early.
No indirect comparison was conducted given the lack
of a common comparator among the three treatments of
interest in the above clinical studies. A mixed-treatment
comparison lied outside the aim of the simulation exer-
cise which was to operationalise the new value frame-
work through the elicitation of preferences across a
range of explicit criteria from a group of stakeholders.
As a result, for the case of cetuximab and panitumumab
clinical evidence was used from a latest head to head,
open label, randomised, multicentre Phase 3 non-infer-
iority study directly comparing both treatments
(ASPECCT trial) [33], whereas for the case of aflibercept
in combination with non-oxaliplatin based chemother-
apy evidence was used from the same clinical study that
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NICE considered. However, data from the BSC compara-
tor arms of the two trials that NICE considered as part
of TA242 for the case of cetuximab and panitumumab
(CO.17, AMGEN) [65, 73] were used for the purpose of
setting the reference levels on the attributes.
Setting attribute ranges and reference levels (model
building)
For the case of clinical therapeutic attributes, the “higher
reference” levels were normally based on BSC figures,
coming from the median of the respective arms of the
CO.17 and AMGEN trials; otherwise, if no BSC figure
was available the placebo comparator arm from the VEL-
OUR trial was used. The “lower reference” levels were
based on the worst performances plausible, inferred ei-
ther based on their lowest natural limit (for the case of
continuous scale attributes, e.g. 0 months for OS) or
based on the lowest evidence-based limit (for the case of
non-natural constructed scale attributes, e.g. 0.6 utility
for HRQoL as it was the lower utility used for progres-
sive disease by NICE). The maximum levels of the attri-
butes were simply derived by adding a 10% absolute
increment to the performance level of the best perform-
ing option, essentially offering an error margin to the
limits of the scale. This was performed to produce refer-
ence levels that corresponded to “worst performance”
(plausible) and “satisfactory performance” (proxied by
BSC), corresponding to the 0 and 100 anchor levels of
the value function scale respectively, with options per-
forming better than the satisfactory level scoring more
than 100. By this way three attribute levels were defined
in total: i) the “lower reference” level (x_l) (i.e. worst per-
formance plausible), acting on the same time as mini-
mum level (x_*); ii) the “higher reference” level (x_h) (i.e.
BSC-based satisfactory performance); and iii) the max-
imum level (x^*) (i.e. 10% higher than the best performing
option), to give x_*≤x_l < x_h< x^*.
For the purpose of eliciting preferences and producing
the matrix of judgements using M-MACBETH, we aimed
to incorporate two additional intermediate attribute levels
lying in-between the three defined attribute levels (giving
a total of five different attribute levels) so that the granu-
larity of the scale is increased, essentially to improve the
representation of any differences in value across the attri-
bute ranges. In cases where the gaps between the three
defined levels were disproportionate large, a third inter-
mediate level was added for a more homogeneous disper-
sion, giving a total of six attribute levels (three defined and
three intermediates), whereas in cases of disproportionate
small gaps only one intermediate level was added giving a
total of four attribute levels (three defined and one inter-
mediate). In no cases there were less than four and more
than six attribute levels in total.
Similar but reverse logic was adopted for setting the
reference levels of the safety attributes; the “higher
reference” levels were based either on the median of
the BSC arm from the AMGEN trial and the placebo
comparator arm of the VELOUR trial (BSC data from
the CO.17 trial were not available for all attributes),
or if this was not relevant on the median of the op-
tions (e.g. for the case of the existence of contra-indi-
cations). The “lower reference” levels were derived
either by adding a 10% absolute increment to the
worst performing option (e.g. 10% higher incidence
for the case of AEs) or by choosing the worst per-
formance plausible for the case of a constructed attri-
bute with a non-continuous scale (i.e. for the
existence of contra-indications). The maximum level
of the attributes was defined by selecting the best
performance plausible (e.g. 0% for incidence of AEs),
whereas the minimum level (i.e. worst performance)
was equal to the “lower reference” level.
For the innovation attributes, the “higher reference”
level was derived by using the median of the options
(BSC performance was irrelevant to be used as satisfac-
tory level), whereas the “lower reference” level was based
on the worst performance plausible as inferred from the
lowest limit of the scales (e.g. 5th entrance at an ATC
level, or 0 number of new indications for which the
technology is investigated in a given clinical develop-
ment stage). The maximum level of the attributes was
derived by either adding a 10% absolute increment to
the performance level of the best performing option, for
the case of natural attributes with a continuous scale
(e.g. number of new indications for which the technol-
ogy is investigated in a given clinical development stage),
or alternatively by using the best performance plausible
for the case of constructed attributes with discrete-level
scales (e.g. 1st entrance at an ATC level). The minimum
level was equal to the “lower reference” level.
For the socioeconomics attribute (impact on direct
costs), the “higher reference” level was derived by
using the median of the options (BSC performance
was irrelevant to be used as satisfactory level), and
the “lower reference” level was derived by adding a
10% absolute increment to the worst performing op-
tion (i.e. to the one with the biggest impact on costs.
The maximum level was defined by selecting the best
performance plausible, as inferred from the highest
natural limit of the scale (i.e. £0 impact on costs),
whereas the minimum level (i.e. worst performance)
was equal to the “lower reference” level.
Decision conference (model assessment and appraisal)
Participants were contacted through an email invitation
outlining the exercise and the purpose of the project,
and background material introducing the scope of the
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exercise in more detail was sent one week before the
workshop.
In terms of the decision-aiding methodology used,
one of the authors (GM) acted as an impartial facili-
tator with the aim of enhancing content and process
interaction, while refraining from contributing to the
content of the group’s discussions, essentially guiding
the group in how to think about the issues but not
what to think [44, 75]. In terms of facilities, the room
of the workshop had a Π-shaped meeting table for all
the participants to have direct eye to eye contact,
with an overhead projector screen surrounded by
whiteboards. The M-MACBETH software was oper-
ated by one of the authors (AA) using a laptop, the
screen of which was connected to the projector.
The workshop lasted the whole day, from 9.00 am
to 18.00 pm with one 45-minutes lunch break, and
two 15-minutes coffee breaks. The day started with a
brief introduction by one of the authors (PK) and
then moved on with an overview of the MCDA meth-
odology adopted and the description of the value tree.
The value tree was then presented and analysed
cluster by cluster.
At the beginning of each cluster the value tree was val-
idated; the various criteria were explained, followed by a
group discussion relating to their relevance and com-
pleteness. As a result of this iterative process, some of
the criteria were excluded because they were perceived
as irrelevant or non-fundamental, but no criteria were
deemed to be missing. Then, value functions were elic-
ited for the different criteria and criteria weights were
elicited within the clusters. Finally, relative weights were
assigned across clusters, which enabled calculating the
overall WPV scores of the options.
MCDA technique (model assessment and appraisal)
MACBETH uses seven semantic categories ranging
between “no difference” to “extreme difference”, in
order to distinguish between the value of different at-
tribute levels. Based on these qualitative judgements
of difference and, by analysing judgmental inconsist-
encies, it facilitates the move from ordinal preference
modeling, a cognitively less demanding elicitation of
preferences, to a quantitative value function. An ex-
ample of the type of questioning being asked would
be “What do you judge to be the difference of value
between x’ and “x”?” where x’ and “x” are two differ-
ent attribute levels of attribute x, across the plausible
range (i.e. x* ≤ x’, “x” ≤ x
*). The approach has evolved
through the course of theoretical research and real
world practical applications, making it an interactive
decision support system that facilitates decision
makers’ communication.
Following the elicitation of value functions, criteria
baseline weights can be elicited. Questions of direct
importance for a criterion such as “How important is
a given criterion?” are known to be as one of the most
common mistakes when making value trade-offs be-
cause they are assessing them independent of the re-
spective attribute ranges [76]. In contrast, indirect
weighting techniques that assess value trade-offs in
tandem with the respective ranges of attributes should
be employed. For example, the quantitative swing
weighting technique asks for judgments of relative
value between “swings” (i.e. changes, from standard
lower level x_l to higher reference level x_h on each x-
th attribute) taking the form “How would you rank the
relative importance of the criteria considering their at-
tribute ranges, relative to 100 for the highest-ranked
criterion?”. Each swing, i.e. a relative change from a
lower attribute level to a higher attribute level, is val-
ued between 0 and 100, with the most valuable swing
anchored as 100 [24]. Normalised weights are then
calculated, as a proportion of each swing weight, so
the normalised weights are summed to 100%. Instead,
relative attribute weights were calculated using an al-
ternative qualitative swing weighting protocol, by
using the MACBETH procedure to elicit the differ-
ences in attractiveness between the lower and higher
reference levels of the different attributes, initially at
individual level and then at criteria cluster level (i.e.
by considering multiple attribute swings on the same
time) [48, 49].
Finally criteria preference value scores and the respect-
ive weights can be combined together through an addi-
tive aggregation approach as described in Eq. 2 (if the
conditions of complete and transitive preferences are
met as well as multi-attribute preferential independence
conditions) [24].
Options performance, criteria weights and overall
preference value rankings
Example of value judgements matrices for the Overall
Survival and Health Related Quality of Life attributes
and their conversion into value functions using the M-
MACBETH software:
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* Images produced using the M-MACBETH (beta)
software version 3.0.0
Caption: In this example, the question asked for the
case of OS was the following: “What do you judge to be
the difference of value between 0 months OS and 3
months OS? No difference, very weak, weak, moderate,
strong, very strong, or extreme?” Once a consensus was
reached, the next question came along: “What do you
judge to be the difference of value between 0 months OS
and 6.2 months OS? No difference, very weak, weak,
moderate, strong, very strong, or extreme?” The same
process was followed until value judgments for all the
different combinations of attribute levels were elicited,
filling in the different rows from the right-hand side (i.e.
lower range) to the left-hand side (i.e. higher range), bot-
tom to top.
Sensitivity and robustness analysis
Sensitivity analysis on weights for Cetuximab versus
Panitumumab:
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Sensitivity analysis on weights for Panitumumab vs
Aflibercept plus FOLFIRI:
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Sensitivity analysis on weights for Cetuximab vs Afli-
bercept plus FOLFIRI:
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Robustness analysis on reference levels:
Caption: Red triangles denote “dominance” (an option
dominates another if it is at least as attractive as the
other in all criteria and it is more attractive than the
other in at least one criterion). Green crosses denote
“additive dominance” (an option additively dominates
another if it is always found to be more attractive than
the other through the use of an additive model under a
set of information constraints).
For more information please see M-MACBETH user
manual [53].
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